322 related articles for article (PubMed ID: 31033480)
1. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
Kellish P; Shabashvili D; Rahman MM; Nawab A; Guijarro MV; Zhang M; Cao C; Moussatche N; Boyle T; Antonia S; Reinhard M; Hartzell C; Jantz M; Mehta HJ; McFadden G; Kaye FJ; Zajac-Kaye M
J Clin Invest; 2019 Apr; 129(6):2279-2292. PubMed ID: 31033480
[TBL] [Abstract][Full Text] [Related]
2. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.
Zemp FJ; McKenzie BA; Lun X; Reilly KM; McFadden G; Yong VW; Forsyth PA
Cancer Res; 2014 Dec; 74(24):7260-73. PubMed ID: 25336188
[TBL] [Abstract][Full Text] [Related]
3. Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.
Weng M; Gong W; Ma M; Chu B; Qin Y; Zhang M; Lun X; McFadden G; Forsyth P; Yang Y; Quan Z
Mol Cancer; 2014 Apr; 13():82. PubMed ID: 24725816
[TBL] [Abstract][Full Text] [Related]
4. Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice.
Morales-Molina Á; Gambera S; Cejalvo T; Moreno R; Rodríguez-Milla MÁ; Perisé-Barrios AJ; García-Castro J
Cancer Immunol Immunother; 2018 Oct; 67(10):1589-1602. PubMed ID: 30066102
[TBL] [Abstract][Full Text] [Related]
5. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
[TBL] [Abstract][Full Text] [Related]
6. Transplantation of autologous bone marrow pre-loaded
Villa NY; Rahman MM; Mamola J; Sharik ME; de Matos AL; Kilbourne J; Lowe K; Daggett-Vondras J; D'Isabella J; Goras E; Chesi M; Bergsagel PL; McFadden G
Oncotarget; 2022; 13():490-504. PubMed ID: 35251496
[TBL] [Abstract][Full Text] [Related]
7. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
Lun X; Alain T; Zemp FJ; Zhou H; Rahman MM; Hamilton MG; McFadden G; Bell J; Senger DL; Forsyth PA
Cancer Res; 2010 Jan; 70(2):598-608. PubMed ID: 20068158
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic myxoma virus: the path to clinic.
Chan WM; Rahman MM; McFadden G
Vaccine; 2013 Sep; 31(39):4252-8. PubMed ID: 23726825
[TBL] [Abstract][Full Text] [Related]
9. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
[TBL] [Abstract][Full Text] [Related]
10. Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection.
Wunder T; Schmid K; Wicklein D; Groitl P; Dobner T; Lange T; Anders M; Schumacher U
Cancer Gene Ther; 2013 Jan; 20(1):25-32. PubMed ID: 23196273
[TBL] [Abstract][Full Text] [Related]
11. Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.
Wennier ST; Liu J; Li S; Rahman MM; Mona M; McFadden G
Mol Ther; 2012 Apr; 20(4):759-68. PubMed ID: 22233582
[TBL] [Abstract][Full Text] [Related]
12. Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton.
Irwin CR; Favis NA; Agopsowicz KC; Hitt MM; Evans DH
PLoS One; 2013; 8(12):e84134. PubMed ID: 24391902
[TBL] [Abstract][Full Text] [Related]
13. Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.
Zemp FJ; McKenzie BA; Lun X; Maxwell L; Reilly KM; McFadden G; Yong VW; Forsyth PA
PLoS One; 2013; 8(6):e65801. PubMed ID: 23762429
[TBL] [Abstract][Full Text] [Related]
14. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
Li H; Wang H; Deng K; Han W; Hong B; Lin W
Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic adenovirus targeting cyclin E overexpression repressed tumor growth in syngeneic immunocompetent mice.
Cheng PH; Rao XM; Wechman SL; Li XF; McMasters KM; Zhou HS
BMC Cancer; 2015 Oct; 15():716. PubMed ID: 26475304
[TBL] [Abstract][Full Text] [Related]
16. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
17. Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer.
Villa NY; Franco LS; McFadden G
Methods Mol Biol; 2020; 2058():95-110. PubMed ID: 31486033
[TBL] [Abstract][Full Text] [Related]
18. Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model.
Nounamo B; Liem J; Cannon M; Liu J
Mol Ther Oncolytics; 2017 Sep; 6():90-99. PubMed ID: 28875159
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.
Madlambayan GJ; Bartee E; Kim M; Rahman MM; Meacham A; Scott EW; McFadden G; Cogle CR
Leuk Res; 2012 May; 36(5):619-24. PubMed ID: 22341701
[TBL] [Abstract][Full Text] [Related]
20. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
